Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome

被引:128
作者
Kol, S [1 ]
机构
[1] Rambam Med Ctr, Dept Obstet & Gynecol, IVF Unit, IL-31096 Haifa, Israel
关键词
OHSS; prevention; GnRH agonist; GnRH antagonist; luteolysis; ovarian stimulation; ovulation;
D O I
10.1016/j.fertnstert.2003.05.032
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To review the available knowledge on the use of GnRH agonist for ovulation triggering as a means to prevent ovarian hyperstimulation syndrome (OHSS). Design(s): Review of pertinent English language studies published over the past 15 years. Result(s): The available literature suggests that while GnRH agonist effectively induces final oocyte maturation and ovulation, it also completely and reliably prevents clinically significant OHSS. The mechanism of action in the context of OHSS prevention involves complete, quick, and irreversible luteolysis. Conclusion(s): Controlled ovarian stimulation protocols based on GnRH antagonist to prevent premature LH rise and GnRH agonist for ovulation triggering provide a safe and OFISS-free clinical environment. Adequate luteal support compensates for luteolysis and assures good clinical outcome. The fertility community is urged to adopt these protocols. This will make OHSS a disease of the past. (Fertil Steril(R) 2004;81:1-5. 02004 by American Society for Reproductive Medicine.)
引用
收藏
页码:1 / 5
页数:5
相关论文
共 33 条
[1]   Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation [J].
Albano, C ;
Smitz, J ;
Camus, M ;
RiethmullerWinzen, H ;
VanSteirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1997, 67 (05) :917-922
[2]   Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome - An aggressive, but perhaps life-saving procedure [J].
Amarin, ZO .
HUMAN REPRODUCTION, 2003, 18 (04) :659-664
[3]  
Borm G, 2000, HUM REPROD, V15, P1490
[4]   Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose [J].
Buckett, WM ;
Bentick, B ;
Shaw, RW .
HUMAN REPRODUCTION, 1998, 13 (04) :811-814
[5]  
DAMEWOOD MD, 1989, FERTIL STERIL, V52, P398
[6]   High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization [J].
de Jong, D ;
Macklon, NS ;
Mannaerts, BMJL ;
Bennink, HJTC ;
Fauser, BCJM .
HUMAN REPRODUCTION, 1998, 13 (03) :573-575
[7]   TRIGGERING OVULATION WITH ENDOGENOUS LUTEINIZING-HORMONE MAY PREVENT THE OVARIAN HYPERSTIMULATION SYNDROME [J].
EMPERAIRE, JC ;
RUFFIE, A .
HUMAN REPRODUCTION, 1991, 6 (04) :506-510
[8]   Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization [J].
Fauser, BC ;
de Jong, D ;
Olivennes, F ;
Wramsby, H ;
Tay, C ;
Itskovitz-Eldor, J ;
van Hooren, HG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :709-715
[9]   PRESERVED PITUITARY-RESPONSE UNDER OVARIAN STIMULATION WITH HMG AND GNRH ANTAGONISTS (CETRORELIX) IN WOMEN WITH TUBAL INFERTILITY [J].
FELBERBAUM, RE ;
REISSMANN, T ;
KUPKER, W ;
BAUER, O ;
ALHASANI, S ;
DIEDRICH, C ;
DIEDRICH, K .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1995, 61 (02) :151-155
[10]   TRIGGERING OF OVULATION IN HUMAN MENOPAUSAL GONADOTROPIN-STIMULATED CYCLES - COMPARISON BETWEEN INTRAVENOUSLY ADMINISTERED GONADOTROPIN-RELEASING-HORMONE (100-MU-G AND 500-MU-G), GNRH AGONIST (BUSERELIN, 500-MU-G) AND HUMAN CHORIONIC-GONADOTROPIN (10000-IU) [J].
GERRIS, J ;
VITS, AD ;
JOOSTENS, M ;
VANROYEN, E .
HUMAN REPRODUCTION, 1995, 10 (01) :56-62